40 results about "HER2 Positive Breast Cancer" patented technology

Methods of treating patients having HER2-positive cancer are provided. Certain methods involve treatment of HER2 positive breast cancer using a programmed cell death protein 1 (PD-1) binding antagonist or a programmed death ligand 1 (PD-L1) binding antagonist in combination with trastuzumab and pertuzumab or with trastuzumab emtansine. The treatment regimen may be used in various clinical settings, for example, for treatment in the neoadjuvant or metastatic setting.

Methods for identifying a cancer patient, such as a breast cancer patient, suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib, and an AKT inhibitor, comprising detecting modulated expression of HER2 (ERBB2) and SASH1 or protein encoded thereof and detecting PIK3CA mutation status. High levels of expression in HER2 and high levels of SASH1 and/or positive PIK3CA mutation status indicate a patient that is suitable for treatment with a 4-anilinoquinazoline kinase inhibitor, such as lapatinib and an AKT inhibitor.

Compounds of formula (I)

in which:

R¹ is:

R² is —CH₃ or —CH₂CH₃; or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions including the compound of formula (I) and a pharmaceutically acceptable carrier. Processes for preparing the compound of formula (I).

Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof. Methods of treating pancreatic cancer in a subject in need of treatment for pancreatic cancer. Methods of treating HER2 positive breast cancer in a subject in need of treatment for HER2 positive breast cancer. Methods of treating drug resistant non-small cell lung cancer in a subject in need of treatment for drug resistant non-small cell lung cancer. Each of these methods can include administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments. Other cancers associated with SHP2 deregulation include HER2-positive breast cancer, triple-negative breast cancer, ductal carcinoma of the breast, invasive ductal carcinoma of the breast, non-small cell lung cancer, esophageal cancer, gastric cancer, squamous-cell carcinoma of the head and neck (SCCHN), and colon cancer.

The invention provides a polypeptide compound with a HER2 targeting function. The polypeptide compound with the HER2 targeting function is formed by connecting a HER2 affinity with a bifunctional chelating agent through a polypeptide sequence; the polypeptide sequence is Met-Val-Lys; the general structural formula of the polypeptide compound is shown in formula (I) as shown in specification, wherein R is a HER2 affinity molecule and X is a bifunctional chelator group. The invention also provides a radiolabelled complex targeting HER2 by taking the polypeptide compound as a ligand. The radiolabeled complex provided by the invention can be used as a radioactive diagnostic probe for evaluating the HER2 receptor of breast cancer, and the probe can reduce the concentration of the kidney under the condition of keeping the uptake of the tumor unchanged, so that the target-to-non-target ratio of the tumor is improved, and the radiation dose to the kidney is reduced. The invention also provides a preparation method of the polypeptide compound and the radiolabelled complex, and application of the polypeptide compound and the radiolabelled complex in preparation of a HER2 positive breast cancer radioactive diagnosis and treatment probe for humans or animals.

The present invention discloses a fusion protein for treating a breast cancer, wherein the fusion protein is Her2 single-chain fragment antibody-polypeptide, the Her2 single-chain fragment antibody is capable of targeting a Her2 receptor locating on a surface of a breast cancer cell, and the polypeptide is capable of carrying siRNA. The polypeptide includes a protamine polypeptide. The siRNA includes PLK1-siRNA, which is capable of restraining an expression of a knubble malignant phenotype gene. The fusion protein for treating the breast cancer is capable of carrying the PLK1-siRNA, and targeting and importing a Her2 positive breast cancer cell specifically, so as to bring the medicament into the cell. The treatment of the breast cancer is capable of generating a strong effect for restraining the breast cancer growth and transfer, may break a gene suppression effect of the existing antisense oligonucleotide and ribozyme, and becames a novel anti-Her2 gene medicament for treating the breast cancer.

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

The invention relates to medicine technical field, and particularly relates to a preparation method of a trastuzumab-mediated cis-platinum targeting conjugate and application of the trastuzumab-mediated cis-platinum targeting conjugate in the preparation of a breast cancer resistant drug. Amphiphilic block copolymer methoxy polyethylene glycol-polyglutamic acid (mPEG-PGA) prepared from methoxypolyethylene glycol amine and 5-benzyl L-glutamate N-carboxyanhydrie is used as a base material for preparation of cis-platinum loading nano balls through the membrane dialysis method, and a carrier is connected with trastuzumab by carrier surface carboxyl group to prepare the trastuzumab-mediated cis-platinum targeting conjugate. The trastuzumab-mediated cis-platinum targeting conjugate can be targeted to enrich chemotherapy drugs in tumor site so as to directly kill tumor cells, reduce the side and toxic effects of traditional antitumor drugs, and trastuzumab targeting therapy of HER2 positive breast cancer patients can be implemented. The trastuzumab-mediated cis-platinum targeting conjugate can cleverly realize trastuzumab and cis-platinum combined targeted drug delivery way, and has good application prospect in treatment of breast cancer by combination of trastuzumab and chemotherapy.

The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.

The invention discloses a breast cancer prognosis evaluating marker and application, and belongs to the technical field of biology. The invention aims to find a marker for effectively evaluating breast cancer prognosis. TCGA, GEO and DNA methylation data of the whole genome level autonomously generated based on a sequencing technology are integrated, it is revealed that the tumor center is in a hypoxic state compared with the tumor edge, survival analysis finds that the HR of a CpG site cg15190451 is smaller than 1, it shows that the breast cancer progress risk is reduced along with increase of the methylation level, and the higher the level is, the patient prognosis is better; and it is prompted that the breast cancer prognosis effect can be judged according to the methylation level of the gene SLC16A5 where cg15190451 is located. The breast cancer prognostic marker is obtained by verifying hypoxia markers in an HER2 positive breast cancer sample on the basis of the expression level of SLC16A5, the breast cancer prognostic evaluation efficiency can be improved, the cost is saved, and the marker is suitable for popularization and application and has a good application prospect.

The invention discloses application of aspirin and herceptin combination or synergy in oncotherapy, and relates to the technical field of oncotherapy. Relative to alone using of herceptin, aspirin is combined with the herceptin for medication, proliferation of HER2 positive tumor cells can be obviously restrained, and apoptosis of the HER2 positive tumor cells is promoted; and effect of anti-HER2 positive tumor of aspirin and herceptin combination for medication is better than effect of alone using of the herceptin. According to the application of aspirin and herceptin combination or synergy in oncotherapy, new application of the aspirin is discovered for the first time, and the aspirin helps to increase curative effect of the herceptin; and through the application of aspirin and herceptin combination or synergy in preparation of medicines used for treating tumors, theoretical basis is not only provided for anticancer effect of the aspirin in HER2 positive tumors, meanwhile, but also a new idea and a treatment mean are provided for treatment of tumors, especially HER2 positive tumors such as HER2 positive breast cancer or HER2 positive gastric cancer.

This invention relates to a complex for cancer cell chemotherapy and, more particularly, to a HER2 aptamer-anticancer drug complex for chemotherapy of cancer cells, which includes a nucleic acid aptamer specifically binding to HER2 and an anticancer drug linked with the nucleic acid aptamer, so that HER2-positive breast cancer cells are selectively targeted and killed.

The invention provides fusion protein. The fusion protein is formed by connecting adjuvant protein with the end N or the end C of a tumor-associated antigen through a linker or a direct connecting mode. The adjuvant protein contains Haemophilus influenzae (Hi) protein D or a segment of the Haemophilus influenzae (Hi) protein D; the tumor-associated antigen contains HER2 protein with the amino acid sequence being SEQ ID NO:3 or a segment of the HER2 protein. The invention further provides a preparing method for the fusion protein and application thereof. The prepared recombined protein can restrain proliferation of HER2 positive breast cancer cells in a Blab/c mice body, or delay the increase speed of breast tumors.

The invention relates to a molecular marker for early screening of a breast cancer. The molecular marker is a phosphorylated antigen fragment, a sequence of the molecular marker is shown as SEQ ID NO.1, and serine residues in the antigen are phosphorylated residues. The breast cancer comprises Luminal A, Luminal B, a HER2 positive breast cancer and a triple negative breast cancer. The invention also relates to a detection reagent capable of identifying the molecular marker and a detection kit containing the detection reagent.